Webcast: Expand Your Process Screening for Viral-based Therapies

Screen Smarter Not Harder: Expand and Accelerate Your Cell Line and Viral Vector Screening

Viral-based therapies like gene therapy or vaccine development require broad and thorough process screening before transitioning into optimization. Screening sets the stage to choose the best performing media, key parameters, and cell lines with minimal variability before optimizing the critical process parameters (CPPs) and critical quality attributes (CQAs).

In this 15-minute webcast, Sartorius's Andres Castillo and Shanya Jiang, PhD present an automated and data-driven methodology for media selection during early process development to streamline development and ultimately accelerate time-to-market.

Watch now for more on:

Automated, high-throughput, multi-parallel investigation using a sophisticated design of experiments (DoE) approach.
Characterizing and quantifying cell line and virus production.
Data-analytics software suites that can be applied throughout the process to quickly obtain illuminating insights.

Clear form data

Please Complete the Form

First Name *

Last Name *

E-Mail *

Phone Number *

Company *

Job Title *

Address *

Country *

Postal Code *

I would like to sign up for newsletters from Sartorius (Sartorius AG and its affiliated companies) based of my personal interests.
I can revoke my consent at any time with effect for the future by sending an e-mail to unsubscribe@sartorius.com or by clicking on the "unsubscribe" link in e-mails I have received.

* These fields are required Information on the use of your data can be found in our privacy policy

Complete Form to Access the File

Andres Castillo

Portfolio Manager | Cell Culture Technologies

Andres Castillo is a Portfolio Manager for Cell Culture Technologies, within the Bioprocess Solutions division at Sartorius. He holds a BS and MBA from the University of Washington. He is working on the execution of Sartorius' global cell culture technology strategy, developing application notes and webinars. Before joining Sartorius in 2021, Andres worked as research scientist in both GMP and non-GMP settings, specializing in cell therapy manufacturing and gene editing applications.

Shanya Jiang, Ph.D.

Portfolio Manager

Shanya Jiang is a Portfolio Manager with experience in cell-based therapies for neurodegenerative diseases. Shanya has a Ph.D. degree in Biomedical Sciences and has over 12 years of experience working with immune cells and stem cells prior to joining Sartorius. She was most recently a Research Scientist at the University of New Mexico working on Alzheimer's disease biomarker discovery and therapies using stable cell lines transduced with lentivirus and iPSC-derived neurons/microglial cells.